US Patent Issued to Alnylam Pharmaceuticals on June 24 for "Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof" (Massachusetts Inventors)

ALEXANDRIA, Va., June 25 -- United States Patent no. 12,338,439, issued on June 24, was assigned to Alnylam Pharmaceuticals Inc. (Cambridge, Mass.).

"Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof" was invented by Akin Akinc (Needham, Mass.), Gregory Hinkle (Plymouth, Mass.), Martin A. Maier (Belmont, Mass.), James Butler (Lynnfield, Mass.) and Jingxuan Liu (West Roxbury, Mass.).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present invention relates to RNAi agents, e.g., double stranded RNAi agents, targeting the Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1) gene, the Factor XII (Hageman Factor (F...